VivoSeq
Cardiovascular

Abdominal Aortic Aneurysm

25

Pipeline Programs

6

Active Trials

19

Companies Involved

Abdominal Aortic Aneurysm is an emerging landscape with 25 programs across 19 companies. The most active players are Amgen, AstraZeneca, Institut de Recherches Internationales Servier. 11 therapies are approved with 2 more in late-stage development.

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

6/100

Mech. Concentration

11/100

Completion Rate

73/100

Attrition Rate

16/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Modality Breakdown

90%

Small molecule

28 of 31 classified programs — the dominant modality here.

10%ALL OTHERSMonoclonal antibody26%Cell therapy13%

Small molecule leads; the ring shows all 31 classified programs, each share of the total. Modality classified for 100% of 31 pipeline programs.

Trial Status

25

clinical trials

Completed11 · 44%
Unknown status4 · 16%
Terminated4 · 16%
Recruiting4 · 16%
Not yet recruiting1 · 4%
Active, not recruiting1 · 4%

Trial Activity

25 trials

GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis Post-Approval Study
Active, not recruiting·WW.L.Gore & Associates·Preclinical·NCT06578741·310 enrolled
Statin Use in Abdominal Aortic Aneurysm Repair
Completed·UUniversity of Hull·Phase 4·NCT01062802·40 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)